<DOC>
	<DOC>NCT00254800</DOC>
	<brief_summary>The purpose of this study is the examine the effect of taking exenatide on the blood levels (pharmacokinetics) of orally-administered contraceptives.</brief_summary>
	<brief_title>The Effects of Exenatide on Oral Contraceptive Pharmacokinetics in Healthy Females</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<mesh_term>Contraceptives, Oral</mesh_term>
	<mesh_term>Levonorgestrel</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<criteria>Premenopausal female of childbearing potential. Body Mass Index (BMI) between 19 and 35 kg/m^2, inclusive. On implanted contraceptives for 6 months, or injectable contraceptives for 12 months prior to the study. Evidence of diabetes mellitus. Participation in a study involving administration of an investigational compound within the past 3 months.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>diabetes</keyword>
	<keyword>exenatide</keyword>
	<keyword>Amylin</keyword>
	<keyword>Lilly</keyword>
</DOC>